Paolo Bossi, MD, University of Brescia, Brescia, Italy, gives an overview of a recent study investigating the factors predicting the outcome of immunotherapy in patients with recurrent/metastatic head and neck cancer. This retrospective study involved a cohort with patients treated with immunotherapy who had achieved an overall survival (OS) greater than 18 months, and another cohort with patients treated with the same therapy but with an OS inferior to 6 months. Dr Bossi explains that gene expression analysis of tissue samples from patients in both of these cohorts revealed that the tumours from patients in the long-term survivor group had a different gene expression profile. These differences in gene expression could help identify patients that could benefit from immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Dr Bossi reports consultant/advisory board participation for BMS, MSD, Merck, Sanofi.